Literature DB >> 15052220

Vascular endothelial growth factor transgene expression in cell-transplanted hearts.

Terrence M Yau1, Guangming Li, Richard D Weisel, Adili Reheman, Zhi-Qiang Jia, Donald A G Mickle, Ren-Ke Li.   

Abstract

OBJECTIVE: We evaluated the effect of transplanted cell type, time, and region of the heart on transgene expression to determine the potential of combined gene and cell delivery for myocardial repair.
METHODS: Lewis rats underwent myocardial cryoinjury 3 weeks before transplantation with heart cells (a mixed culture of cardiomyocytes, smooth muscle cells, endothelial cells and fibroblasts, n = 13), vascular endothelial growth factor-transfected heart cells (n = 13), skeletal myoblasts (n = 13), vascular endothelial growth factor-transfected skeletal myoblasts (n = 13), or medium (control, n = 12). Vascular endothelial growth factor expression in the scar, border zone, and normal myocardium was evaluated at 3 days and at 1, 2, and 4 weeks by means of quantitative polymerase chain reaction. Transplanted cells and vascular endothelial growth factor protein were identified immunohistologically on myocardial sections.
RESULTS: Vascular endothelial growth factor levels were very low in control scars but increased transiently after medium injection. Transplantation with heart cells and skeletal myoblasts significantly increased vascular endothelial growth factor expression in the scar and border zone. Transplantation of vascular endothelial growth factor-transfected heart cells and vascular endothelial growth factor-transfected skeletal myoblasts further augmented vascular endothelial growth factor expression, resulting in 4- to 5-fold greater expression of vascular endothelial growth factor in the scar at 1 week. Peak vascular endothelial growth factor expression was greater and earlier in vascular endothelial growth factor-transfected heart cells than in vascular endothelial growth factor-transfected skeletal myoblasts. Vascular endothelial growth factor was primarily expressed by the transplanted cells. Some of the transplanted heart cells and vascular endothelial growth factor-transfected heart cells were identified in the endothelial layer of blood vessels in the scar.
CONCLUSIONS: Transplantation of heart cells and skeletal myoblasts induces vascular endothelial growth factor expression in myocardial scars and is greatly augmented by prior transfection with a vascular endothelial growth factor transgene. Vascular endothelial growth factor expression is limited to the scar and border zone for 4 weeks. Both heart cells and skeletal myoblasts may be excellent delivery vehicles for cell-based myocardial gene therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15052220     DOI: 10.1016/j.jtcvs.2003.09.052

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  10 in total

Review 1.  Nonviral vector gene modification of stem cells for myocardial repair.

Authors:  Husnain K Haider; Ibrahim Elmadbouh; Michel Jean-Baptiste; Muhammad Ashraf
Journal:  Mol Med       Date:  2008 Jan-Feb       Impact factor: 6.354

2.  Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs.

Authors:  Rupak Mukherjee; Juozas A Zavadzkas; Stuart M Saunders; Julie E McLean; Laura B Jeffords; Christy Beck; Robert E Stroud; Allyson M Leone; Christine N Koval; William T Rivers; Shubhayu Basu; Alexander Sheehy; Gene Michal; Francis G Spinale
Journal:  Ann Thorac Surg       Date:  2008-10       Impact factor: 4.330

Review 3.  "Second-generation" stem cells for cardiac repair.

Authors:  Alberto Núñez García; Ricardo Sanz-Ruiz; María Eugenia Fernández Santos; Francisco Fernández-Avilés
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

4.  Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium.

Authors:  I Elmadbouh; Husnain Kh Haider; Shujia Jiang; Niagara Muhammad Idris; Gang Lu; Muhammad Ashraf
Journal:  J Mol Cell Cardiol       Date:  2007-02-08       Impact factor: 5.000

Review 5.  Stem cell paracrine actions and tissue regeneration.

Authors:  Priya R Baraniak; Todd C McDevitt
Journal:  Regen Med       Date:  2010-01       Impact factor: 3.806

6.  Ephrin-Eph signaling as a potential therapeutic target for the treatment of myocardial infarction.

Authors:  Wesley T O'Neal; William F Griffin; Jessica L Dries-Devlin; Susan D Kent; Jin Chen; Monte S Willis; Jitka A I Virag
Journal:  Med Hypotheses       Date:  2013-04-04       Impact factor: 1.538

7.  EphrinA1-Fc attenuates myocardial ischemia/reperfusion injury in mice.

Authors:  Augustin DuSablon; Justin Parks; K'Shylah Whitehurst; Heather Estes; Robert Chase; Eleftherios Vlahos; Uma Sharma; David Wert; Jitka Virag
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.240

Review 8.  Optimizing stem cells for cardiac repair: Current status and new frontiers in regenerative cardiology.

Authors:  Shant Der Sarkissian; Thierry Lévesque; Nicolas Noiseux
Journal:  World J Stem Cells       Date:  2017-01-26       Impact factor: 5.326

9.  Effects of implantation of bone marrow cells on cytokine levels in the ischemic heart tissue. An experimental study.

Authors:  Yahya Unlu; Sami Karapolat
Journal:  J Cardiothorac Surg       Date:  2008-05-20       Impact factor: 1.637

10.  EphA2-receptor deficiency exacerbates myocardial infarction and reduces survival in hyperglycemic mice.

Authors:  Augustin DuSablon; Susan Kent; Anita Coburn; Jitka Virag
Journal:  Cardiovasc Diabetol       Date:  2014-08-13       Impact factor: 9.951

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.